ENDP - エンド―・インタ―ナショナル （Endo International plc） エンド―・インタ―ナショナルENDPのチャート
ENDPの企業情報
| symbol | ENDP |
|---|---|
| 会社名 | Endo International plc （エンド―・インタ―ナショナル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 エンド・インターナショナル(Endo International PLC)(旧名：Endo Health Solutions Inc.)はブランドおよびジェネリック医薬品、デバイス及びサービスの提供に集中する専門医療ソリューション会社である。同社のブランド医薬品のポートフォリオは「Lidoderm」、「Opana ER」、「Voltaren Gel」、「Percocet」、「Frova」、「Supprelin LA」、「Vantas」、「Valstar」及び「Fortesta Gel」を含む。同社はEndo医薬品事業、Qualitest事業、AMS事業、及びHealthTronics事業という４つの事業セグメントを運営する。HealthTronics事業を通じて、同社は砕石サービス、前立腺治療サービス、解剖病理学サービス、医療製品の製造・販売・保守、および情報技術ソリューションを提供する。Qualitest製品ポートフォリオには、「Endocet」、「Morphine Sulfate ER」及び「Hydrocodone」等がある。AMS事業は「AMS 700 MS」、「AMS 800」人工尿道括約筋、「GreenLight XPS」レーザーシステム及び「Monarc」筋膜下ハンモックを提供する。Endo医薬品事業は「Lidoderm」、「Opana ER」、「Voltaren Gel」及び「Percocet」等がある。 エンド―・インタ―ナショナルは医薬品企業。主な医薬品は痛みに対する治療薬、泌尿器、内分泌および腫瘍に関連する痛みのブランド治療薬、また、泌尿器、免疫抑制、腫瘍、女性特定疾患、高血圧などに対するジェネリック医薬品も含む。また、骨盤を治療する医療デバイスや技術を医師に提供。本社はアイルランドのダブリン。 Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them. |
| 本社所在地 | First Floor Minerva House Simmonscourt Road Ballsbridge Dublin 4 IRL |
| 代表者氏名 | Roger H. Kimmel ロジャー・キンメル |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +353 1-268-2000 |
| 設立年月日 | 41548 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 3039人 |
| url | www.endo.com |
| nasdaq_url | https://www.nasdaq.com/symbol/endp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 1451.299 |
| 終値（lastsale） | 17.08 |
| 時価総額（marketcap） | 3824763410.72 |
| 時価総額 | 時価総額（百万ドル） 3941.208 |
| 売上高 | 売上高（百万ドル） 2970.75 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 11109.63 |
| 当期純利益 | 当期純利益（百万ドル） -957.70100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Endo International PLC revenues decreased 26% to $1.42B. Net loss before extraordinary items decreased 36% to $550.2M. Revenues reflect Generics segment decrease of 47% to $490.5M U.S. Branded - Specialty_Established Pharmaceuticals segment decrease of 17% to $412.9M United States segment decrease of 25% to $1.34B International segment decrease of 41% to $78.2M. |
ENDPのテクニカル分析
ENDPのニュース
Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes 2021/03/11 23:35:00 PR Newswire
DUBLIN, March 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") priced $1.295 billion…
Endo International plc Announces Proposed Private Offering Of Senior Secured Notes 2021/03/11 12:33:00 PR Newswire
DUBLIN, March 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") intend to offer senior…
Endo International plc Commences Refinancing of its Existing Term Loan 2021/03/04 12:30:00 PR Newswire
DUBLIN, March 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it has commenced a refinancing of its existing $3.3 billion senior secured term loan due 2024 with the net proceeds of a new senior secured term loan and other debt issuances. The new…
Leerink Partners Stick to Their Hold Rating for Endo International By Investing.com 2021/03/02 14:49:07 Investing.com
Leerink Partners Stick to Their Hold Rating for Endo International
Endo International Must-See Earnings Estimates for: Stock market Insights & financial analysis 2021/02/24 18:23:00 Stock Market Daily
Endo International announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes 2021/03/11 23:35:00 PR Newswire
DUBLIN, March 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") priced $1.295 billion…
Endo International plc Announces Proposed Private Offering Of Senior Secured Notes 2021/03/11 12:33:00 PR Newswire
DUBLIN, March 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") intend to offer senior…
Endo International plc Commences Refinancing of its Existing Term Loan 2021/03/04 12:30:00 PR Newswire
DUBLIN, March 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it has commenced a refinancing of its existing $3.3 billion senior secured term loan due 2024 with the net proceeds of a new senior secured term loan and other debt issuances. The new…